Are Clinical Trials Safe? Understanding Risks, Monitoring, and Protection

Safety is the first question almost everyone asks before considering a clinical trial — and it's the right question. The honest answer is: clinical trials carry real risks, but they are among the most tightly monitored medical activities in existence. Understanding how that monitoring works is what separates informed patients from frightened ones.

The Honest Answer

Yes, clinical trials carry risk. That is not a reason to avoid them — it is a fact you need to understand so you can make an informed decision.

All medical interventions carry risk. The standard-of-care drugs you take today were once investigational. Every medication on the market was, at some point, unknown territory. The question is never “is there zero risk?” — it's always “are the potential benefits worth the potential risks, given what I know?”

What distinguishes clinical trials from other medical activities is how aggressively those risks are monitored and managed. The regulatory and ethical systems built around clinical research exist precisely because the people designing them knew the risks were real.

What Makes Trials Risky

The core of clinical trial risk is uncertainty. When a trial begins, the treatment being tested hasn't been fully proven in humans. That's why the trial exists. Some of the specific risks include:

• Unknown side effects. Laboratory and animal studies predict many effects, but not all. Human biology can respond in unexpected ways.
• Randomization. In randomized controlled trials, some participants receive the experimental treatment and others receive a placebo or current standard of care. You may not get the experimental drug.
• More time and visits. Trials require more monitoring than standard care — more blood draws, imaging, clinic visits. Each of these carries minor procedural risks.
• The drug may not work. Experimental treatments fail more often than they succeed. Most Phase 2 trials don't lead to approved drugs.

These risks are real — but they exist within a framework of oversight designed to detect problems as early as possible and protect participants when they emerge.

How Safety Is Overseen: IRBs

Before a single participant joins a clinical trial, an Institutional Review Board (IRB) must approve it. IRBs are independent committees of physicians, researchers, patient advocates, and community members whose sole function is to evaluate whether a proposed trial is ethical and safe enough to conduct.

An IRB reviews:

• The full trial protocol — study design, dose levels, safety stopping rules
• The informed consent document — what participants are told about risks and benefits
• Whether the potential benefits justify the risks for this patient population
• Whether vulnerable populations (children, pregnant women, cognitively impaired individuals) are adequately protected
• Researcher qualifications and site infrastructure

IRBs are required by federal regulation (the “Common Rule” and FDA regulations) for any trial involving human subjects in the United States. Without IRB approval, a trial simply cannot begin.

Importantly, IRB oversight continues throughout the trial. Researchers must submit periodic reports, and any serious adverse event must be reported to the IRB promptly. The IRB can suspend or terminate a trial at any time if safety concerns arise.

Real-Time Monitoring: DSMBs and Safety Reviews

For larger trials, a second layer of safety oversight is added: the Data Safety Monitoring Board (DSMB), sometimes called a Data Monitoring Committee (DMC). The DSMB is an independent group of experts — typically clinicians and statisticians unaffiliated with the trial sponsor — who receive blinded or unblinded safety data during the trial in real time.

The DSMB meets periodically (often every 6–12 months) to review accumulating safety data and can recommend:

• Stopping the trial early if harm is being observed
• Stopping early for benefit if the treatment is clearly working and it would be unethical to continue withholding it from the control group
• Modifying the protocol — changing doses, narrowing eligibility, or adding monitoring
• Continuing as planned if the safety profile looks acceptable

Additionally, all serious adverse events must be reported to the FDA and the IRB within defined timeframes. The FDA can also place a clinical hold — effectively pausing a trial — if significant safety signals emerge.

Your Right to Stop — Always

One of the most important protections in any clinical trial is this: you can withdraw at any time, for any reason, without penalty or loss of your regular medical care.

This is not a formality buried in the fine print. It is a foundational principle of research ethics grounded in the Belmont Report and the Declaration of Helsinki. You cannot be coerced into staying. You cannot be denied your regular treatment for withdrawing. You cannot lose benefits you are entitled to.

If you develop side effects that concern you, if your life circumstances change, if you simply change your mind — you tell the research coordinator. That's it. You leave. The team may ask to follow up with you for safety purposes (to monitor any lingering effects of the study drug), but you have the right to decline even that.

How Risk Varies by Phase

Not all trials carry the same level of risk. Phase significantly predicts the risk profile:

The Difference Between Risk and Harm

It's worth distinguishing between risk and harm. Risk is the possibility that something bad might happen. Harm is when it does. Most clinical trial participants experience risk — but the majority complete trials without serious harm.

Common minor adverse events in trials include fatigue, injection site reactions, nausea, and headache — similar to what many approved drugs cause. Serious adverse events (those requiring hospitalization, causing disability, or deemed life-threatening) do occur but are carefully tracked and trigger mandatory reporting.

For context: standard medical care also carries risk. Approved drugs cause side effects. Surgeries carry complications. The ethical question for any trial is whether the risk level is reasonable given what participants might gain — and whether participants understand and accept that risk freely.

Questions to Ask About Safety

Before you agree to join any trial, ask the research coordinator these questions:

• What are the most common side effects seen so far in this study?
• What are the most serious potential side effects?
• What is the safety monitoring plan — is there a DSMB?
• What happens if I experience a serious side effect? Who do I call?
• Will the trial sponsor cover costs if I'm injured?
• Can I continue my current medications while in the trial?
• What happens to my regular care if I withdraw?
• Has this drug already been tested in Phase 1 or Phase 2? What did those results show?

A research team that can't answer these questions clearly — or that discourages you from asking — is a warning sign.

Frequently Asked Questions

Are clinical trials safer than they used to be?

Yes. Modern clinical trial regulation — especially post-1970s reforms following the Tuskegee scandal and the passage of the Belmont Report — is vastly more stringent than earlier eras. IRBs, informed consent requirements, DSMB oversight, and FDA reporting rules are all relatively recent. Historical abuses are well-documented precisely because today's system was built to prevent them.

What if I'm injured during a trial?

You should ask this before you enroll. Most trial sponsors provide free medical care for injuries directly caused by the study drug or procedure. However, coverage for injury-related lost wages or long-term disability varies widely. Read the informed consent form carefully, and ask explicitly what the sponsor will cover.

Can I be in a trial if I'm already taking other medications?

It depends on the trial. Some trials have strict exclusions on concomitant medications to avoid drug interactions or confounding results. Others are flexible. Disclose everything you take — including supplements — and ask the research coordinator what's allowed.

Is it safer to join a Phase 3 trial than a Phase 1?

Generally speaking, yes. Phase 3 trials have more human safety data behind them. But “safer” is relative — some Phase 3 drugs carry significant toxicity (particularly in oncology), while some Phase 1 trials test drugs with very well-understood safety profiles from prior studies. Phase matters, but it's not the only thing that matters.

Can I be kicked out of a trial?

Yes — investigators can remove participants for safety reasons (e.g., a lab value becomes dangerous), protocol violations, or if the trial is stopped entirely. This is done for your protection, not as a punishment. The research team should explain next steps for your care if this happens.

Who do I call if something goes wrong?

The informed consent form must include a 24-hour emergency contact for safety concerns. Keep this number saved. For non-emergency concerns, the research coordinator is your primary point of contact.